Physician profile
Shari Topper
NPI 1962402545
$15,751.24
in general payments reported to CMS, 2019-2025
36 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $19.99 · 2021: $567 · 2022: $720 · 2023: $3,568 · 2024: $9,135 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,640 · Food and Beverage: $5,161 · Travel and Lodging: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,640.00 |
| Food and Beverage | $5,161.02 |
| Travel and Lodging | $2,261.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $8,391.48 | 2022-2024 | Vtama |
| Organon LLC | $1,182.56 | 2024-2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $1,167.14 | 2023-2025 | Zoryve |
| Abbvie INC. | $618.81 | 2021-2025 | Skyrizi, Botox, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $472.73 | 2021-2025 | Dupixent |
| Amgen INC. | $461.21 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $426.42 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $354.56 | 2022-2025 | |
| Almirall LLC | $343.97 | 2021-2025 | Seysara |
| Novartis Pharmaceuticals Corporation | $319.78 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $304.92 | 2023-2025 | Sotyktu |
| Incyte Corporation | $259.05 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $247.30 | 2019-2025 | Adbry, Anzupgo |
| Prugen, INC. Pharmaceuticals | $216.14 | 2019 | |
| Sun Pharmaceutical Industries INC. | $128.11 | 2019-2023 | Odomzo, Blu-U, Winlevi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $106.46 | 2019-2024 | Aklief, Epsolay |
| Lilly USA, LLC | $93.74 | 2022-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $82.51 | 2021-2025 | Tremfya |
| Musculoskeletal Transplant Foundation INC. | $74.86 | 2023 | |
| Allergan, INC. | $72.34 | 2021-2022 | |
| Botanix Sb INC | $60.58 | 2025 | Sofdra |
| Epi Health, LLC | $49.77 | 2019-2020 | |
| Pfizer INC. | $46.12 | 2022-2023 | |
| Krystal Biotech INC | $45.58 | 2024 | Vyjuvek |
| Lnhc, INC | $32.66 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.85 | 2022 | |
| Mayne Pharma Commercial LLC | $21.01 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.78 | 2023 | Jublia, Arazlo |
| Strata Skin Sciences, INC. | $20.78 | 2025 | Xtrac |
| Organogenesis INC. | $17.87 | 2021 | |
| Vyne Pharmaceuticals INC. | $16.85 | 2021 | |
| Nabriva Therapeutics, Plc | $13.77 | 2021 | |
| Promius Pharma LLC | $13.68 | 2019 | |
| Biofrontera INC. | $13.59 | 2021 | |
| Dusa Pharmaceuticals, INC. | $11.76 | 2019 | |
| Merck Sharp & Dohme LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Topper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.